Andrew Judd
Grayslake,IL
Summary
Accomplished Research Fellow at AbbVie, specializing in drug discovery and medicinal chemistry. Proven track record in leading multidisciplinary teams to develop innovative antibody-drug conjugates and small molecules. Adept in scientific project leadership and mentoring, with a focus on achieving clinical milestones and advancing therapeutic candidates.
Overview
23
23
years of professional experience
Work History
Research Fellow
AbbVie, Inc.
06.2021 - Current
Project Leader for Top1i(p)_Top1i(lp) Dual ADC Project
- Leading a multidisciplinary team to identify potent lower permeability Top1i payloads for use in Next Gen Dual Top1i cMET ADCs, as a bolster strategy for ABBV-400. Team is currently characterizing dual payload ADCs for in vivo efficacy and therapeutic index, anticipating a 2Q26 Candidate Nomination transition.
Co-Project Leader for the TAK-1 Inhibitor Project
- Leading a multidisciplinary team to identify potent orally bioavailable TAK-1 inhibitors for the treatment of ovarian cancer and other solid tumor indications. Team is currently characterizing advanced leads for a 4Q25 Candidate Nomination transition.
STING Agonists for Intravenous (IV) dosing
- As Chemistry Team Lead, guided the Lead Optimization (LO) campaign of a multi-site team of chemists from Lake County, Sygnature and Wuxi to identify potent and pan-polymorphism active STING agonists suitable for IV dosing.
- As Project Director for the STING Agonist program, led a multidisciplinary team to characterize and evaluate monomer A-1974219 and dimer A-1966554 as potential CS candidates. The program successfully achieved the CS milestone in April 2022. Based on its superior profile that is consistent with best-in-class, dimer A-1966554 was nominated as GLP tox candidate ABBV-973.
Other Job Responsibilities
- Responsible for managing the Oncology Medicinal Chemistry Team at Lake County (25 FTE)
- Mentored junior researchers, providing guidance on study design, data analysis, and manuscript preparation.
- Member of AbbVie Drug Candidate Leadership Team (DCLT), responsible for reviewing program chemical matter prior to Lead Optimization transitions.
Sr. Principal Research Scientist
AbbVie, Inc.
06.2017 - 06.2021
Chemistry Team Leader
Small molecule MCL-1 Inhibitors for Intravenous (IV) dosing
- Led the Lead Optimization (LO) campaign of a multi-site team of chemists from Lake County, Ludwigshafen, Inventiva and Wuxi to identify potent and selective MCL-1 inhibitors suitable for IV dosing. This work culminated in the identification of ABBV-164 and ABBV-467, the latter assessed in Phase 1 clinical trials.
- Led efforts to identify ABBV-467 back up molecules compatible with non-Kolliphor based formulation vehicles. The team identified pre-clinical candidate A-1763637, a compound with 5-folds lowered projected human dose (20 mg) than ABBV-467. A-1763637 is subject to studies with human serum albumin and liposomal formulations as a potential back up to ABBV-467.
- Led efforts to identify water soluble MCL-1 inhibitor prodrugs for intravenous delivery. The team identified A-1797586, an ammonium phosphate prodrug with excellent solubility (>0.5 mg/mL at pH7.4), greater than 50% bioavailability of API across species, and projected human dose of 50 mg. Ultimately, development of A-1797586 was ceased due to unexpected acute dog CV findings, a phenomenon not previously encountered with the parent API, even at high multiples of predicted human Cmax.
Small molecule MCL-1 Inhibitors for Oral dosing
- Led a multi-site team of chemists from Lake County, Ludwigshafen, Sygnature (UK), HDB and Wuxi to identify potent and selective, orally bioavailable MCL-1 inhibitors. The program achieved an LO transition in February 2020, and the LO team has identified lead compounds with 6-46-folds lowered projected human doses relative to the clinical benchmark AMG397. Advanced lead compounds, A-196330, A-1975357 and A-1965631, with a range of projected human half-lives (8-30 h) were assessed in dose-range finding toxicology studies and are consistent with Candidate Nomination assets.
BCL-2 B2 Program
- Supervised the medicinal chemistry activities of the BCL-2 component of the B2 program. Responsibilities included coaching and consulting with direct report who was primarily responsible for leading chemistry optimization activities. The team ultimately identified multiple GLP tox candidates, culminating in the advancement of ABBV-623 to PhI clinical trials.
BCL-2/XL Dual Inhibitors Program (Navitoclax 2.0)
- Supervised and consulted with direct report who was primarily responsible for leading chemistry optimization activities. The team identified structurally novel dual inhibitors with a range of profiles including “navitoclax-like” and “next generation,” the latter with improved potency and oral pharmacokinetics. Leads from each category are currently being profiled as potential CN candidates.
Other Job Responsibilities
- MedChem 2025 Committee Member contributing to “Bro5 Best Practices” whitepaper.
- Active member of the Discovery Chemistry Mentorship Program. Mentored five G17 chemists (two currently) and hosted an ACOS Circles session for new hires.
Principal Research Scientist
AbbVie, Inc.
06.2013 - 07.2017
BCL-XLi Antibody Drug Conjugates
- Led the BCL-XL chemistry team to develop novel, potent and efficacious ADC warheads. A suite of warheads spanning a range of solubility and permeability was developed and utilized to investigate the therapeutic index of targeted BCL-XL inhibition. Ultimately, warheads containing polar, uncharged moieties were instrumental in managing an unexpected toxicology finding that limited the progression of earlier BCL-XLtargeting ADCs; culminated in the identification of clinical candidates B7H3-targeting ABBV-155 and EGFR-targeting ABBV-637 currently in Phase 1 clinical trials, and GLP tox candidate ABBV-1013.
- Key leader in cross-area (LC Discovery, PRD, ABC) efforts to develop Abbvie’s solubilizing linkers and attachments for ADC applications. Solubilizing linkers and attachments developed in this work are now used company-wide to enable lipophilic warheads.
Small molecule MCL-1 Inhibitor for Intravenous Dosing
- Led a multi-site team of chemists from Lake County, Ludwigshafen, Wuxi and Inventiva to develop novel MCL-1 inhibitors. Novel macrocyclic inhibitors demonstrated robust in vivo efficacy as single agent and in combination with ABT-199. The program achieved an LO transition in September 2016.
Other Job Resonsibilities
- Member of Chemistry Recruiting Committee
- Member of due diligence teams for Serina Therapeutics (polyvalent linkers) and RedX Pharma (reversible BTKi) technology evaluations.
Chemistry Group Leader
Abbott Laboratories
02.2011 - 06.2013
Novel Payloads for Antibody-drug Conjugates (ADCs)
- Maintained a leadership role in a multi-disciplinary team assembled to identify and validate novel classes of ADC warheads. The team identified potent tool BCL-XLi-based ADCs with good properties, validated their in vitro effects as “on-target” and “on-mechanism,” and demonstrated in vivo efficacy with an improved therapeutic window in rodents relative to small molecule treatment.
- Team identified potent tool NAMPTi-based ADCs with good properties, characterized their in vitro behavior and established in vivo proof of concept. The program was advanced to lead generation status in 2016.
- Collaborated with colleagues in Molecular Probes and Immunology chemistry to build a “Linker Toolkit” for use by the Global ADC Team.
- Member of Early Discovery ADC Leadership Team with lead roles in the New Technologies and Linker sub-teams.
BCL-XL Inhibitor Collaboration with Genentech
- Led a team of nine chemists in the identification of potent, selective, and orally bioavailable BCL-XL inhibitors. The compounds demonstrated in vivo efficacy and successfully validated the hypothesis that adjuvant treatment of a selective BCL-XL inhibitor does not exacerbate neutropenia associated with taxotere treatment.
- Supervised the chemistry portion of a detailed investigation into mechanism-based toxicity, which ultimately allowed for the team to make a timely data-driven decision to terminate the small molecule project.
- Responsible for communicating the chemistry strategy and research updates to Genentech collaborators in biweekly teleconferences and at quarterly meetings.
Other Job Responsibilities
- Ad Hoc member of Chemistry Recruiting Committee (2012)
- Ad Hoc member of Future of Oncology Drug Discovery Committee (2012)
- Member of MCLT Technology Sub-committee (2011)
Senior Scientist III
Abbott Laboratories
06.2009 - 02.2011
CDK Inhibitors for oncology
- Optimized a 7-azaindole screening hit to give the key tool compound A-1261346, a selective CDK9 inhibitor that displayed inhibition of RNAP II CTD Ser2 phosphorylation in vitro and in vivo. The series was transferred to Aurigene for further optimization and variants remain under investigation at Abbvie.
- Designed and synthesized a novel class of 6-substituted-8-cycloalkyl-pyridazinonepyrimidines and demonstrated that appropriate 6-substitution could tune either selective CDK4/6 or Wee-1 inhibition. The 6-aryl variants were transferred to the Wee-1 team, where they were subject to intensive lead optimization.
Aurora B Inhibitors Back up program for oncology
- Coordinated a team of 5 chemists in the development of novel 7-azaindoles as 2nd generation dual inhibitors of Aurora-1 and KDR. Compounds had improved physicochemical properties and were efficacious in tumor xenograft models.
Other Job Responsibilities
- Member of the File Enrichment Committee (2009-2010), responsible for design and selection of monomers for the Abbott monomer collection
Associate Research Investigator
Abbott Laboratories
06.2005 - 06.2009
Structure-oriented Synthesis, Advanced Technology
- Designed and synthesized ligands for prostanoid GPCRs.
- Mentored Master’s level Summer Intern and co-developed a method for the concise synthesis of bridged bicyclic lactams.
Metabolic Disease Research
- Coordinated a team of 7 medicinal chemists in efforts to identify novel drug candidates in the DGAT-1 program.
- Primary inventor of the “meso” series of DGAT-1 inhibitors.
- Performed 6-month Process Chemistry rotation; received Abbott Spot Award for conception and implementation of a mole-scale synthesis of DPP-IV inhibitor ABT-341.
Other Job Responsibilities
- Member of New Drug Targets Committee
- Served as Discovery recruiter to UT at Austin and UI-Urbana/Champagne.
Senior Research Scientist
Abbott Laboratories
06.2002 - 06.2005
Metabolic Disease Research
- Developed potent and efficacious MCHr1 antagonists with minimal hERG channel activity
- Had a lead role in the SAR development of potent and selective AMPK activators with improved oral exposure
Education
NIH Postdoctoral Fellow
University of Texas At Austin
Austin, TX01-2002
Ph.D. - Organic Chemistry
University of Minnesota
Minneapolis, MN12-1999
Bachelor of Science - Chemistry, With Honors
Eckerd College
St. Petersburg, FL06-1994
Skills
- Drug Discovery
- Medicinal Chemistry
- Antibody Drug Conjugates
- Beyond Rule-of-5 Drugs
- Protein-Protein Interactions
- IV Drugs
- DMPK, CMC
- Advance Data Analysis
- Research design
- Scientific writing
- Scientific project leadership
- People Mentoring and Development
Publications
(1) Judd, A. S.; Bawa, B.; Buck, W. R.; Tao, Z.-F.; Li, Y.; Mitten, M. J.; Bruncko, M.; Catron, N.; Doherty, G.; Durbin, K. R.; Enright, B.; Frey, R.; Haasch, D.; Haman, S.; Haight, A. R.; Henriques, T. A.; Holms, J.; Izeradjene, K.; Judge, R. A.; Jenkins, G. J.; Kunzer, A.; Leverson, J. D.; Martin, R. L.; Mitra, D.; Mittelstadt, S.; Nelson, L.; Nimmer, P.; Palma, J.; Peterson, R.; Phillips, D. C.; Ralston, S. L.; Rosenberg, S. H.; Shen, X.; Song, X.; Vaidya, K. R.; Wang, X.; Wang, J.; Xiao, Y.; Zhang, H.; Zhang, X.; Blomme, E. A.; Boghaert, E. R.; Kalvass, J. C.; Phillips, A.; Souers, A. J. BCL-XL-targeting antibody-drug conjugates are active in preclinical models and mitigate on-mechanism toxicity of small-molecule inhibitors. Sci. Adv. 2024, 10 (40), eado7120. DOI: 10.1126/sciadv.ado7120.
(2) Yuda, J.; Will, C.; Phillips, D. C.; Abraham, L.; Alvey, C.; Avigdor, A.; Buck, W.; Besenhofer, L.; Boghaert, E.; Cheng, D.; Cojocari, D.; Doyle, K.; Hansen, T. M.; Huang, K.; Johnson, E. F.; Judd, A. S.; Judge, R. A.; Kalvass, J. C.; Kunzer, A.; Lam, L. T.; Li, R.; Martin, R. L.; Mastracchio, A.; Mitten, M.; Petrich, A.; Wang, J.; Ward, J. E.; Zhang, H.; Wang, X.; Wolff, J. E.; Bell-McGuinn, K. M.; Souers, A. J. Selective MCL-1 inhibitor ABBV-467 is efficacious in tumor models but is associated with cardiac troponin increases in patients. Commun. Med. 2023, 3 (1), 154. DOI: 10.1038/s43856-023-00380-z.
(3) Brady, P. B.; Sorensen, B. K.; Risi, R. M.; Curtin, M. L.; Mantei, R. A.; Florjancic, A. S.; Mastracchio, A.; Ji, C.; Kunzer, A. R.; Lai, C.; Storer, G. E.; Chan, V. S.; Henry, R. F.; Souers, A. J.; Michaelides, M. R.; Judd, A. S.; Hansen, T. M. An Enabling, Decagram-Scale Synthesis of Macrocyclic MCL-1 Inhibitor ABBV-467. J. Org. Chem. 2023, 88(22), 15562-15568. DOI: 10.1021/acs.joc.3c00939.
(4) Bai, W.-J.; Estrada, M. A.; Gartman, J. A.; Judd, A. S. Enantioselective Bioreduction of Medicinally Relevant Nitrogen-Heteroaromatic Ketones. ACS Med. Chem. Lett. 2023, 14 (6), 846-852. DOI: 10.1021/acsmedchemlett.3c00114.
(5) Tao, Z.-F.; Wang, X.; Chen, J.; Ingram, J. P.; Jin, S.; Judge, R. A.; Kovar, P. J.; Park, C.; Sun, C.; Wakefield, B. D.; Zhou, L.; Zhang, H.; Elmore, S. W.; Phillips, D. C.; Judd, A. S.; Leverson, J. D.; Souers, A. J. Structure-Based Design of A-1293102, a Potent and Selective BCL-XL Inhibitor. ACS Med. Chem. Lett. 2021, 12 (6), 1011-1016. DOI: 10.1021/acsmedchemlett.1c00162.
(6) Wang, L.; Doherty, G. A.; Judd, A. S.; Tao, Z.-F.; Hansen, T. M.; Frey, R. R.; Song, X.; Bruncko, M.; Kunzer, A. R.; Wang, X.; Wendt, M. D.; Flygare, J. A.; Catron, N. D.; Judge, R. A.; Park, C. H.; Shekhar, S.; Phillips, D. C.; Nimmer, P.; Smith, M. L.; Tahir, S. K.; Xiao, Y.; Xue, J.; Zhang, H.; Le, P. N.; Mitten, M. J.; Boghaert, E. R.; Gao, W.; Kovar, P.; Choo, E. F.; Diaz, D.; Fairbrother, W. J.; Elmore, S. W.; Sampath, D.; Leverson, J. D.; Souers, A. J. Discovery of A-1331852, a First-in-Class, Potent, and Orally-Bioavailable BCL-XL Inhibitor. ACS Med. Chem. Lett. 2020, 11 (10), 1829-1836. DOI: 10.1021/acsmedchemlett.9b00568.
(7) Yeh, V. S. C.; Beno, D. W. A.; Brodjian, S.; Brune, M. E.; Cullen, S. C.; Dayton, B. D.; Dhaon, M. K.; Falls, H. D.; Gao, J.; Grihalde, N.; Hajduk, P.; Hansen, T. M.; Judd, A. S.; King, A. J.; Klix, R. C.; Larson, K. J.; Lau, Y. Y.; Marsh, K. C.; Mittelstadt, S. W.; Plata, D.; Rozema, M. J.; Segreti, J. A.; Stoner, E. J.; Voorbach, M. J.; Wang, X.; Xin, X.; Zhao, G.; Collins, C. A.; Cox, B. F.; Reilly, R. M.; Kym, P. R.; Souers, A. J. Identification and preliminary characterization of a potent, safe, and orally efficacious inhibitor of Acyl-CoA: Diacylglycerol acyltransferase 1. J. Med. Chem. 2012, 55 (4), 1751-1757. DOI: 10.1021/jm201524g.
(8) Ravn, M. M.; Wagaw, S. H.; Engstrom, K. M.; Mei, J.; Kotecki, B.; Souers, A. J.; Kym, P. R.; Judd, A. S.; Zhao, G. Process Development of a Diacyl Glycerolacyltransferase-1 Inhibitor. Org. Process Res. Dev. 2010, 14 (2), 417-424. DOI: 10.1021/op900310v.
(9) King, A. J.; Judd, A. S.; Souers, A. J. Inhibitors of diacylglycerol acyltransferase: a review of 2008 patents. Expert Opin. Ther. Pat. 2010, 20 (1), 19-29. DOI: 10.1517/13543770903499305.
(10) Zhao, G.; Souers, A. J.; Voorbach, M.; Falls, H. D.; Droz, B.; Brodjian, S.; Lau, Y. Y.; Iyengar, R. R.; Gao, J.; Judd, A. S.; Wagaw, S. H.; Ravn, M. M.; Engstrom, K. M.; Lynch, J. K.; Mulhern, M. M.; Freeman, J.; Dayton, B. D.; Wang, X.; Grihalde, N.; Fry, D.; Beno, D. W. A.; Marsh, K. C.; Su, Z.; Diaz, G. J.; Collins, C. A.; Sham, H.; Reilly, R. M.; Brune, M. E.; Kym, P. R. Validation of Diacyl Glycerolacyltransferase I as a Novel Target for the Treatment of Obesity and Dyslipidemia Using a Potent and Selective Small Molecule Inhibitor. J. Med. Chem. 2008, 51(3), 380-383. DOI: 10.1021/jm7013887.
(11) Judd, A. S.; Souers, A. J.; Kym, P. R. Lead optimization of melanin concentrating hormone receptor 1 antagonists with low hERG channel activity. Curr. Top. Med. Chem. (Sharjah, United Arab Emirates) 2008, 8 (13), 1152-1157. DOI: 10.2174/156802608785700052.
(12) Zhao, G.; Iyengar, R. R.; Judd, A. S.; Cool, B.; Chiou, W.; Kifle, L.; Frevert, E.; Sham, H.; Kym, P. R. Discovery and SAR development of thienopyridones: A class of small molecule AMPK activators. Bioorg. Med. Chem. Lett. 2007, 17 (12), 3254-3257. DOI: 10.1016/j.bmcl.2007.04.011.
(13) Yeh, V.; Judd, A. S.; Souers, A. J. Lipid-metabolizing enzymes as targets for dyslipidemia and insulin resistance. Annu. Rep. Med. Chem. 2007, 42, 161-175. DOI: 10.1016/s0065-7743(07)42011-5.
(14) Souers, A. J.; Iyengar, R. R.; Judd, A. S.; Beno, D. W. A.; Gao, J.; Zhao, G.; Brune, M. E.; Napier, J. J.; Mulhern, M. M.; Lynch, J. K.; Freeman, J. C.; Wodka, D.; Chen, C. J.; Falls, H. D.; Brodjian, S.; Dayton, B. D.; Diaz, G. J.; Bush, E. N.; Shapiro, R.; Droz, B. A.; Knourek-Segel, V.; Hernandez, L. E.; Marsh, K. C.; Reilly, R. M.; Sham, H. L.; Collins, C. A.; Kym, P. R. Constrained 7-fluorocarboxychromone-4-aminopiperidine based Melanin-concentrating hormone receptor 1 antagonists: The effects of chirality on substituted indan-1-ylamines. Bioorg. Med. Chem. Lett. 2007, 17(4), 884-889. DOI: 10.1016/j.bmcl.2006.11.061.
(15) Ribelin, T. P.; Judd, A. S.; Akritopoulou-Zanze, I.; Henry, R. F.; Cross, J. L.; Whittern, D. N.; Djuric, S. W. Concise Construction of Novel Bridged Bicyclic Lactams by Sequenced Ugi/RCM/Heck Reactions. Org. Lett. 2007, 9 (24), 5119-5122. DOI: 10.1021/ol7023373.
(16) Kym, P. R.; Judd, A. S.; Lynch, J. K.; Iyengar, R.; Vasudevan, A.; Souers, A. J. Lead optimization strategies and tactics applied to the discovery of melanin concentrating hormone receptor 1 antagonists. Curr. Top. Med. Chem. (Sharjah, United Arab Emirates) 2007, 7 (15), 1471-1488. DOI: 10.2174/156802607782194699.
(17) Judd, A. S.; Souers, A. J.; Wodka, D.; Zhao, G.; Mulhern, M. M.; Iyengar, R. R.; Gao, J.; Lynch, J. K.; Freeman, J. C.; Falls, H. D.; Brodjian, S.; Dayton, B. D.; Reilly, R. M.; Gintant, G.; Limberis, J. T.; Mikhail, A.; Leitza, S. T.; Houseman, K. A.; Diaz, G.; Bush, E. N.; Shapiro, R.; Knourek-Segel, V.; Hernandez, L. E.; Marsh, K. C.; Sham, H. L.; Collins, C. A.; Kym, P. R. Identification of diamino chromone-2-carboxamides as MCHr1 antagonists with minimal hERG channel activity. Bioorg. Med. Chem. Lett. 2007, 17 (8), 2365-2371. DOI: 10.1016/j.bmcl.2006.11.068.
(18) Iyengar, R. R.; Lynch, J. K.; Mulhern, M. M.; Judd, A. S.; Freeman, J. C.; Gao, J.; Souers, A. J.; Zhao, G.; Wodka, D.; Falls, H. D.; Brodjian, S.; Dayton, B. D.; Reilly, R. M.; Swanson, S.; Su, Z.; Martin, R. L.; Leitza, S. T.; Houseman, K. A.; Diaz, G.; Collins, C. A.; Sham, H. L.; Kym, P. R. An evaluation of 3,4-methylenedioxy phenyl replacements in the aminopiperidine chromone class of MCHr1 antagonists. Bioorg. Med. Chem. Lett. 2007, 17 (4), 874-878. DOI: 10.1016/j.bmcl.2006.11.065.
(19) Breton, P.; Hergenrother, P. J.; Hida, T.; Hodgson, A.; Judd, A. S.; Kraynack, E.; Kym, P. R.; Lee, W.-C.; Loft, M. S.; Yamashita, M.; Martin, S. F. Total synthesis of erythromycin B. Tetrahedron 2007, 63 (26), 5709-5729. DOI: 10.1016/j.tet.2007.02.044.
(20) Pei, Z.; Li, X.; von Geldern, T. W.; Madar, D. J.; Longenecker, K.; Yong, H.; Lubben, T. H.; Stewart, K. D.; Zinker, B. A.; Backes, B. J.; Judd, A. S.; Mulhern, M.; Ballaron, S. J.; Stashko, M. A.; Mika, A. K.; Beno, D. W. A.; Reinhart, G. A.; Fryer, R. M.; Preusser, L. C.; Kempf-Grote, A. J.; Sham, H. L.; Trevillyan, J. M. Discovery of ((4R,5S)-5-Amino-4-(2,4,5- trifluorophenyl)cyclohex-1-enyl)-(3- (trifluoromethyl)-5,6-dihydro- [1,2,4]triazolo[4,3-a]pyrazin-7(8H)-yl)methanone (ABT-341), a Highly Potent, Selective, Orally Efficacious, and Safe Dipeptidyl Peptidase IV Inhibitor for the Treatment of Type 2 Diabetes. J. Med. Chem. 2006, 49 (22), 6439-6442. DOI: 10.1021/jm060955d.
(21) Lynch, J. K.; Freeman, J. C.; Judd, A. S.; Iyengar, R.; Mulhern, M.; Zhao, G.; Napier, J. J.; Wodka, D.; Brodjian, S.; Dayton, B. D.; Falls, D.; Ogiela, C.; Reilly, R. M.; Campbell, T. J.; Polakowski, J. S.; Hernandez, L.; Marsh, K. C.; Shapiro, R.; Knourek-Segel, V.; Droz, B.; Bush, E.; Brune, M.; Preusser, L. C.; Fryer, R. M.; Reinhart, G. A.; Houseman, K.; Diaz, G.; Mikhail, A.; Limberis, J. T.; Sham, H. L.; Collins, C. A.; Kym, P. R. Optimization of Chromone-2-carboxamide Melanin Concentrating Hormone Receptor 1 Antagonists: Assessment of Potency, Efficacy, and Cardiovascular Safety. J. Med. Chem. 2006, 49 (22), 6569-6584. DOI: 10.1021/jm060683e.
(22) Kym, P. R.; Souers, A. J.; Campbell, T. J.; Lynch, J. K.; Judd, A. S.; Iyengar, R.; Vasudevan, A.; Gao, J.; Freeman, J. C.; Wodka, D.; Mulhern, M.; Zhao, G.; Wagaw, S. H.; Napier, J. J.; Brodjian, S.; Dayton, B. D.; Reilly, R. M.; Segreti, J. A.; Fryer, R. M.; Preusser, L. C.; Reinhart, G. A.; Hernandez, L.; Marsh, K. C.; Sham, H. L.; Collins, C. A.; Polakowski, J. S. Screening for Cardiovascular Safety: A Structure-Activity Approach for Guiding Lead Selection of Melanin Concentrating Hormone Receptor 1 Antagonists. J. Med. Chem. 2006, 49 (7), 2339-2352. DOI: 10.1021/jm0512286.
(23) Souers, A. J.; Gao, J.; Wodka, D.; Judd, A. S.; Mulhern, M. M.; Napier, J. J.; Brune, M. E.; Bush, E. N.; Brodjian, S. J.; Dayton, B. D.; Shapiro, R.; Hernandez, L. E.; Marsh, K. C.; Sham, H. L.; Collins, C. A.; Kym, P. R. Synthesis and evaluation of urea-based indazoles as melanin-concentrating hormone receptor 1 antagonists for the treatment of obesity. Bioorg. Med. Chem. Lett. 2005, 15 (11), 2752-2757. DOI: 10.1016/j.bmcl.2005.03.114.
(24) Souers, A. J.; Gao, J.; Brune, M.; Bush, E.; Wodka, D.; Vasudevan, A.; Judd, A. S.; Mulhern, M.; Brodjian, S.; Dayton, B.; Shapiro, R.; Hernandez, L. E.; Marsh, K. C.; Sham, H. L.; Collins, C. A.; Kym, P. R. Identification of 2-(4-Benzyloxyphenyl)-N- [1-(2-pyrrolidin-1-yl-ethyl)-1H-indazol- 6-yl]acetamide, an Orally Efficacious Melanin-Concentrating Hormone Receptor 1 Antagonist for the Treatment of Obesity. J. Med. Chem. 2005, 48 (5), 1318-1321. DOI: 10.1021/jm0490890.
(25) Kym, P. R.; Iyengar, R.; Souers, A. J.; Lynch, J. K.; Judd, A. S.; Gao, J.; Freeman, J.; Mulhern, M.; Zhao, G.; Vasudevan, A.; Wodka, D.; Blackburn, C.; Brown, J.; Che, J. L.; Cullis, C.; Lai, S. J.; LaMarche, M.; Marsilje, T.; Roses, J.; Sells, T.; Geddes, B.; Govek, E.; Patane, M.; Fry, D.; Dayton, B. D.; Brodjian, S.; Falls, D.; Brune, M.; Bush, E.; Shapiro, R.; Knourek-Segel, V.; Fey, T.; McDowell, C.; Reinhart, G. A.; Preusser, L. C.; Marsh, K.; Hernandez, L.; Sham, H. L.; Collins, C. A. Discovery and Characterization of Aminopiperidinecoumarin Melanin Concentrating Hormone Receptor 1 Antagonists. J. Med. Chem. 2005, 48 (19), 5888-5891. DOI: 10.1021/jm050598r.
(26) Amorde, S. M.; Judd, A. S.; Martin, S. F. Cascade Iminium Ion Reactions for the Facile Synthesis of Quinolizidines. Concise Syntheses of (±)-Epilupinine and (-)-Epimyrtine. Org. Lett. 2005, 7 (10), 2031-2033. DOI: 10.1021/ol050544b.
(27) Hergenrother, P. J.; Hodgson, A.; Judd, A. S.; Lee, W.-C.; Martin, S. F. An abiotic strategy for the enantioselective synthesis of erythromycin B. Angew. Chem., Int. Ed. 2003, 42 (28), 3278-3281. DOI: 10.1002/anie.200351136.
(28) Ayyad, S.-E. N.; Judd, A. S.; Shier, W. T.; Hoye, T. R. Otteliones A and B: Potently Cytotoxic 4-Methylene-2-cyclohexenones from Ottelia alismoides. J. Org. Chem. 1998, 63 (23), 8102-8106. DOI: 10.1021/jo971870a.
(29) Frangione, M.; Port, J.; Baldiwala, M.; Judd, A.; Galley, J.; DeVega, M.; Linna, K.; Caron, L.; Anderson, E.; Goodwin, J. A. Thermochemistry of Oxo Transfer from Coordinated Nitrite in the Dinitro(5,10,15,20-tetrakis(o-pivalamidophenyl)porphinato)iron(III) Anion. Inorg. Chem. 1997, 36 (9), 1904-1911. DOI: 10.1021/ic9608915.
(30) Chenier, P. J.; Judd, A. S.; Raguse, T. L.; Hoye, T. R. Chiral tropocoronands: synthesis and metal complex formation. Tetrahedron Lett. 1997, 38 (42), 7341-7344. DOI: 10.1016/s0040-4039(97)01783-8.
Patents
(1) Doherty, G. A.; Bhat, V.; Brady, P.; Dai, Y.; Gong, J.; Judd, A. S.; Souers, A. J.; Yu, Y. 1,3,4,7-Tetrahydro-2H-pyrrolo[3',2':5,6]pyrido[2,3-b][1,4]oxazepines as Bcl-2 inhibitors and their preparation. WO2023141536, 2023.
(2) Braje, W.; Doherty, G.; Jantos, K.; Ji, C.; Judd, A.; Kunzer, A.; Mastracchio, A.; Song, X.; Souers, A.; Sullivan, G.; Tao, Z.-F.; Teske, J.; Wang, X.; Wendt, M.; Penning, T.; Lai, C.; Kling, A.; Pohlki, F. Preparation of macrocyclic Mcl-1 inhibitors for the treatment of cancer. WO2019035911, 2019.
(3) Braje, W.; Doherty, G.; Jantos, K.; Ji, C.; Judd, A.; Kunzer, A.; Mastracchio, A.; Song, X.; Souers, A.; Sullivan, G.; Tao, Z.-F.; Lai, C.; Kling, A.; Pohlki, F.; Teske, J.; Wendt, M.; Brady, P.; Wang, X.; Penning, T.; Michaelides, M. Preparation of macrocyclic Mcl-1 inhibitors for the treatment of cancer. WO2019035927, 2019.
(4) Brady, P.; Braje, W.; Dai, Y.; Doherty, G.; Gong, J.; Jantos, K.; Ji, C.; Judd, A.; Kunzer, A.; Mastracchio, A.; Risi, R.; Song, X.; Souers, A.; Sullivan, G.; Tao, Z.-F.; Teske, J.; Wang, X.; Wendt, M.; Yu, Y.; Zhu, G.; Penning, T.; Lai, C.; Kling, A.; Pohlki, F.; Potin, D.; Guillier, F. Preparation of macrocyclic Mcl-1 inhibitors for the treatment of cancer. WO2019035914, 2019.
(5) Brady, P.; Braje, W.; Dai, Y.; Doherty, G.; Gong, J.; Jantos, K.; Ji, C.; Judd, A.; Kunzer, A.; Mastracchio, A.; Risi, R.; Song, X.; Souers, A.; Sullivan, G.; Tao, Z.-F.; Teske, J.; Wang, X.; Wendt, M.; Yu, Y.; Zhu, G.; Penning, T.; Lai, C. Macrocyclic compounds as Mcl-1 inhibitors and their preparation and use. WO2019035899, 2019.
(6) Boghaert, E. R.; Souers, A. J.; Phillips, A. C.; Judd, A. S.; Bruncko, M. Anti-EGFR antibody drug conjugates comprising Bcl-xL-inhibitors and anticancer uses thereof. WO2017214282, 2017.
(7) Boghaert, E. R.; Judd, A. S.; Phillips, A. C.; Souers, A. J.; Bruncko, M. Anti-EGFR antibody drug conjugates. WO2017214301, 2017.
(8) Boghaert, E. R.; Bruncko, M.; Doherty, G.; Frey, R. R.; Judd, A. A.; Phillips, A. C.; Song, X.; Souers, A. J.; Sullivan, G. M.; Tao, Z.-F. Anti-EGFR antibody drug conjugates. WO2017214233, 2017.
(9) Benatuil, L.; Bruncko, M.; Judd, A. S.; Li, Y.; McCluskey, A.; Phillips, A. C.; Phillips, D. C.; Seagal, J.; Souers, A. J. Anti-CD98 antibodies and antibody drug conjugates. WO2017214462, 2017.
(10) Benatuil, L.; Bruncko, M.; Doherty, G.; Frey, R. R.; Judd, A. S.; Li, Y.; McCluskey, A.; Phillips, A. C.; Phillips, D. C.; Song, X.; Seagal, J.; Souers, A. J.; Sullivan, G. M.; Tao, Z.-F. Anti-CD98 antibodies and antibody drug conjugates. WO2017214456, 2017.
(11) Benatuil, L.; Bruncko, M.; Chao, D.; Izeradjene, K.; Judd, A. S.; Phillips, A. C.; Souers, A. J.; Thakur, A. Antibodies specific for human B7 homolog 3 protein, sequences and antibody drug conjugates and therapeutic uses thereof. WO2017214335, 2017.
(12) Benatuil, L.; Bruncko, M.; Chao, D.; Izeradjene, K.; Judd, A. S.; Phillips, A. C.; Souers, A. J.; Thakur, A. Anti-B7-H3 antibodies and antibody drug conjugates. WO2017214339, 2017.
(13) Benatuil, L.; Bruncko, M.; Chao, D.; Doherty, G.; Frey, R. R.; Izeradjene, K.; Judd, A. S.; Phillips, A. C.; Song, X.; Souers, A. J.; Sullivan, G. M.; Tao, Z.-F.; Thakur, A. Preparation and therapeutic activity of anti-B7-H3 antibodies and antibody drug conjugates. WO2017214322, 2017.
(14) Tao, Z.-F.; Doherty, G.; Wang, X.; Sullivan, G. M.; Song, X.; Kunzer, A. R.; Wendt, M. D.; Marin, V. L.; Frey, R. R.; Cullen, S. C.; Welch, D. S.; Shen, X.; Bennett, N. B.; Haight, A. R.; Ackler, S. L.; Boghaert, E. R.; Souers, A. J.; Judd, A. S. Preparation of Bcl-xL inhibitory compounds having low cell permeability and antibody drug conjugates containing them. WO2016094509, 2016.
(15) Boghaert, E. R.; Ackler, S. L.; Tao, Z.-F.; Wang, X.; Doherty, G.; Marin, V. L.; Sullivan, G. M.; Song, X.; Kunzer, A. R.; Welch, D. S.; Bruncko, M.; Judd, A. S.; Souers, A. J. Antibody drug conjugates with cell permeable Bcl-xl inhibitors. WO2016094505, 2016.
(16) Ackler, S. L.; Bennett, N. B.; Boghaert, E. R.; Cullen, S. C.; Doherty, G.; Frey, R. R.; Haight, A. R.; Judd, A. S.; Kunzer, A. R.; Shen, X.; Song, X.; Souers, A. J.; Sullivan, G. M.; Tao, Z.-F.; Wang, X.; Welch, D. S.; Wendt, M. D. Bcl-xl inhibitory compounds and antibody drug conjugates including the same. US20160158377, 2016.
(17) Tao, Z.-F.; Wang, X.; Wendt, M. D.; Souers, A. J.; Judd, A. S.; Kunzer, A.; Sullivan, G. Preparation of apoptosis-inducing agents for treatment of cancer, immune and autoimmune diseases. WO2014158528, 2014.
(18) Tao, Z.-F.; Wang, X.; Wendt, M.; Souers, A.; Judd, A.; Kunzer, A.; Sullivan, G. Preparation of apoptosis-inducing agents for treatment of cancer, immune and autoimmune diseases. US20140275082, 2014.
(19) Judd, A. S.; Souers, A. J.; Tao, Z.-F. Apoptosis-inducing agents for treatment of cancer. WO2014028381, 2014.
(20) Zhu, G.; Gong, J.; Judd, A. S.; Ghandi, V. B.; Shoemaker, A. R.; Penning, T. D.; Michaelides, M. R.; Lai, C.; Woods, K. W. Pyridazino[4,5-d]pyrimidin-5(6H)-one as Wee-1 kinase inhibitors and their preparation and use in the treatment of cancer. WO2013013031, 2013.
(21) Wang, L.; Doherty, G.; Wang, X.; Tao, Z.-F.; Brunko, M.; Kunzer, A. R.; Wendt, M. D.; Song, X.; Frey, R.; Hansen, T. M.; Sullivan, G. M.; Judd, A.; Souers, A. Preparation of 8-carbamoyl-2-(2,3-disubstituted pyrid-6-yl)-1,2,3,4-tetrahydroisoquinoline derivatives as apoptosis-inducing agents for the treatment of cancer and immune and autoimmune diseases. WO2013055897, 2013.
(22) Wang, L.; Doherty, G.; Wang, X.; Tao, Z.-F.; Brunko, M.; Kunzer, A. R.; Wendt, M. D.; Song, X.; Frey, R.; Hansen, T. M.; Sullivan, G. M.; Judd, A.; Souers, A. Preparation of substituted benzothiazoles as apoptosis-inducing agents for the treatment of cancer, immune and autoimmune diseases. WO2013055895, 2013.
(23) Clark, R. F.; Sorensen, B.; Osuma, A. T.; Frey, R.; Longenecker, K.; Doherty, G.; Curtin, M. L.; Michaelides, M. R.; Sweis, R. F.; Pliushchev, M. A.; Judd, A.; Hansen, T. M.; Heyman, H. R. Imidazopyridines and related as NAMPT inhibitors and their preparation. WO2013170112, 2013.
(24) Michaelides, M.; Judd, A.; Fix-Stenzel, S. Preparation of pyrrolopyridines and pyrrolopyrimidines as inhibitors of Aurora and KDR kinases for treating cancers. WO2011143459, 2011.
(25) Judd, A. S.; Mulhern, M. M.; Iyengar, R. R.; Kym, P. R.; Souers, A. J. Preparation of thiazole derivatives as inhibitors of diacylglycerol O-acyltransferase type 1 enzyme. WO2008134693, 2008.
(26) Pei, Z.; Geldern, T. V.; Madar, D. J.; Li, X.; Basha, F.; Yong, H.; Longenecker, K. L.; Backes, B. J.; Judd, A. S.; Mulhern, M. M.; Stewart, K. D. Cyclohexenylamine derivatives and as inhibitors of dipeptidyl peptidase-iv (DPP-IV) and their preparation, pharmaceutical compositions and use in the treatment of various diseases. US20070049596, 2007.
(27) Iyengar, R. R.; Zhao, G.; Freeman, J. C.; Gao, J.; Judd, A. S.; Kym, P. R.; Lynch, J. K.; Mulhern, M. M.; Souers, A. J. Cycloalkanecarboxylic acid derivatives as inhibitors of diacylglycerol o-acyltransferase type 1 enzyme and their preparation, pharmaceutical compositions and use in the treatment of diseases. WO2007137107, 2007.
(28) Souers, A. J.; Collins, C. A.; Gao, J.; Judd, A. S.; Kym, P. R.; Mulhern, M. M.; Sham, H. L.; Wodka, D. Preparation of N-indazolylalkanamide and N-indazolylurea derivatives as antagonists of melanin concentrating hormone effects on the melanin concentrating hormone receptor. US20050137187, 2005.
(29) Souers, A. J.; Collins, C. A.; Gao, J.; Judd, A. S.; Kym, P. R.; Mulhern, M. M.; Sham, H. L.; Wodka, D. Preparation of substituted 2H-indazoles as antagonists of the melanin concentrating hormone receptor for eating disorders. US20050187279, 2005.
(30) Souers, A. J.; Collins, C. A.; Gao, J.; Judd, A. S.; Kym, P. R.; Mulhern, M. M.; Sham, H. L.; Wodka, D. Preparation of substituted 1H-indazoles as antagonists of melanin concentrating hormone effects on the melanin concentrating hormone receptor for treating eating disorders. US20050277638, 2005.
(31) Souers, A. J.; Collins, C. A.; Gao, J.; Judd, A. S.; Kym, P. R.; Mulhern, M. M.; Sham, H. L.; Vasudevan, A.; Wodka, D. Preparation of N-indazolylalkanamide and N-indazolylurea derivatives as antagonists of melanin concentrating hormone effects on the melanin concentrating hormone receptor. US20050137243, 2005.
(32) Lynch, J. K.; Collins, C. A.; Freeman, J. C.; Gao, J.; Iyengar, R. R.; Judd, A. S.; Kym, P. R.; Mulhern, M. M.; Sham, H. L.; Souers, A. J.; Zhao, G.; Wodka, D. Preparation of piperidinyl chromenecarboxamides as antagonists of melanin concentrating hormone effects on the melanin concentrating hormone receptor. US20050209274, 2005.
(33) Lynch, J. K.; Collins, C. A.; Freeman, J. C.; Gao, J.; Iyengar, R. R.; Judd, A. S.; Kym, P. R.; Mulhern, M. M.; Sham, H. L.; Souers, A. J.; Zhao, G. Preparation of piperidinyl-chromene carboxamides as antagonists of melanin-concentrating hormone. US20050187387, 2005.
(34) Iyengar, R. R.; Judd, A. S.; Zhao, G.; Kym, P. R.; Sham, H. L.; Gu, Y.; Liu, G.; Liu, M.; Zhao, H.; Clark, R. F.; Frevert, E. U.; Cool, B. L.; Zhang, T.; Keyes, R. F.; Hansen, T. M.; Xin, Z. Preparation of substituted thieno[2,3-b]pyridones as activators for AMP-activated kinase for the treatment of diabetes and obesity. US20050038068, 2005.
Invited Presentations
"Targeted Delivery of BCL-XL Selective Inhibitors Alleviates On-Target Toxicity of Systemically Dosed Inhibitors in Preclinical Models." Judd, A. S., Invited Lecture, 17th Winter Conference on Medicinal and Bioorganic Chemistry, Hanson WAde 3rd ADC Toxicity Summit, Boston MA, July 9, 2025.
"Optimization of a Fragment Hit Yields ABBV-973, a Potent Pan-allele Small Molecule STING Agonist for Intravenous Administration." Judd, A. S., Invited Lecture, Drug Discovery Chemistry, San Diego CA, April 15th, 2025.
"Targeted Delivery of BCL-XL Selective Inhibitors Alleviates On-Target Toxicity of Systemically Dosed Inhibitors in Preclinical Models." Judd, A. S., Invited Lecture, 17th Winter Conference on Medicinal and Bioorganic Chemistry, Steamboat CO, February 5, 2025.
"Molecular Mavericks: Unleashing the Extraordinary Capabilities of Small Molecules to Disrupt Protein-Protein Interactions." Judd, A. S., Invited Lecture, Abbvie ACOS Celebration of Science, Abbott Park IL, October 23, 2024.
"Targeted Delivery of BCL-XL Selective Inhibitors Alleviates On-Target Toxicity of Systemically Dosed Inhibitors in Preclinical Models." Judd, A. S., Invited Lecture, Spring ACS Meeting, New Orleans LA, March 18, 2024.
“Discovery of Selective BCL-XL Inhibitors and Application to Antibody-drug Conjugates.” Judd, A. S., Invited Lecture, ACS Bay Area Chemistry Symposium, South San Francisco, CA, November 8, 2019.
“MCL-1 Inhibitors for IV Dosing in Cancer Patients.” Judd, A. S., Seminar, 2019 Abbvie Medicinal Chemistry Summit, Libertyville, IL, September 20, 2019.
“Discovery and Pre-Clinical Advancement of Selective BCL-XL Inhibitors.” Judd, A. S., Invited Lecture, Zing Conference on Structure-based Drug Design, Carlsbad, CA, February, 2016.
“Discovery and Preclinical Advancement of Selective BCL-XL Inhibitors.” Judd, A. S., Abbvie Residential Chemistry Courses, Abbvie, Inc., July, 2015.
“Development of BCL-XL Inhibitor ADCs.” Judd, A. S. Seminar, 5th Abbott/Abbvie Medicinal Chemistry Summit, Libertyville, IL, 2013.
“Industrial Applications of the RCM Reaction: From “Twisted Amides” to Productive Dimers.” Judd, A. S. Seminar, Bio-Organic Gordon Research Conference, June, 2010.
“Industrial Applications of the RCM Reaction: From “Twisted Amides” to Productive Dimers.” Judd, A. S. Invited Lecture, University of North Carolina-Chapel Hill, March 19, 2009.
“Industrial Applications of the RCM Reaction: From “Twisted Amides” to Productive Dimers” Judd, A. S. Seminar, Abbott Laboratories Chemistry Workshop, University of Minnesota-Twin Cities, Feb 13, 2009.
“Aspects of Drug Design” Judd, A. S. Seminar, Abbott Laboratories Chemistry Workshop, University of Minnesota-Twin Cities, Feb 14, 2009.
“Industrial Applications of the RCM Reaction: From “Twisted Amides” to Productive Dimers.” Judd, A. S. Seminar, 2ndAbbott Laboratories Chemistry Symposium, University of Texas at Austin, Austin, TX, 2008.
“Optimization of DGAT-1 Inhibitors for the Treatment of Dyslipidemia and Other Risk Factors Associated with Metabolic Syndrome.” Judd, A. S. Seminar, 2nd Abbott Medicinal Chemistry Summit, Abbott Park, IL, 2007.
“Studies Directed Toward an Abiotic Synthesis of Erythromycin B.” Judd, A. S.*; Hergenrother, P. J., Hodgson, A.; Lee, W.-C.; Martin, S. F. Poster, 52ndNatural Products Gordon Research Conference, Tilton, NH, 2003.
“New Antitumor Agents: Structure and Synthesis Studies of the Otteliones A and B.” Hoye, T. R.; Ayyad, S.-E. N.; Judd, A. S.*; Shier, W. T. Seminar, 216th ACS Meeting, Boston, MA 1998.
Timeline
Research Fellow
AbbVie, Inc.
06.2021 - Current
Sr. Principal Research Scientist
AbbVie, Inc.
06.2017 - 06.2021
Principal Research Scientist
AbbVie, Inc.
06.2013 - 07.2017
Chemistry Group Leader
Abbott Laboratories
02.2011 - 06.2013
Senior Scientist III
Abbott Laboratories
06.2009 - 02.2011
Associate Research Investigator
Abbott Laboratories
06.2005 - 06.2009
Senior Research Scientist
Abbott Laboratories
06.2002 - 06.2005
NIH Postdoctoral Fellow
University of Texas At Austin
Ph.D. - Organic Chemistry
University of Minnesota
Bachelor of Science - Chemistry, With Honors
Eckerd College